October 9, 2008 - A new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced esophageal cancer, according to a study released at the 73rd Annual Scientific Meeting of the American College of Gastroenterology.
A Phase 2 multi-center study on the safety and long-term efficacy of a new biologic therapy called TNFerade, an injection of an anti-tumor agent, was conducted in 24 patients with locally advanced esophageal cancer.